This website uses cookies to store information on your computer. Some of these cookies are used for visitor analysis, others are essential to making our site function properly and improve the user experience. By using this site, you consent to the placement of these cookies. Click Accept to consent and dismiss this message or Deny to leave this website. Read our Privacy Statement for more.
Join Mailing List   |   Jobs   |   Print Page   |   Contact Us   |   Sign In   |   Join
News & Press: Journals

New Recommendations and Guidelines from the SSC of the ISTH

Friday, August 15, 2014   (0 Comments)
Share |
Prevention of Venous Thromboembolism in Hospitalized Medical Cancer Patients: guidance from the SSC of the ISTH

M. Di Nisio, M. Carrier, G.H. Lyman, A. A. Khorana and the SSC Subcommittee on Haemostasis and Malignancy

Cancer patients hospitalized for an acute medical illness are at increased risk of venous thromboembolism (VTE). Pharmacological thromboprophylaxis is considered standard practice for these patients and current guidelines recommend prophylactic doses of low-molecular-weight heparins (LMWHs), unfractionated heparin (UFH), or fondaparinux in the absence of bleeding or other contraindications [1-4]. These recommendations are extrapolated from large placebo-controlled randomized clinical trials (RCTs) of VTE thromboprophylaxis in broad mixed populations of medical inpatients, none involving exclusively cancer patients or presenting efficacy and safety data for this subgroup [5-8]. Because cancer inpatients represent a unique population with increased risk of VTE and major hemorrhage, validation of the efficacy and safety of thromboprophylaxis in this group is critical.

Membership Management Software Powered by YourMembership  ::  Legal